$0.02
(Market cap
$4 Mln
Recently Viewed
Clear AllMarket cap
$4 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
67.8
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-6.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0
Debt to Equity
-0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,552,430
CFO
$-239.20 Mln
EBITDA
$-315.57 Mln
Net Profit
$-313.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptose Biosciences (APTO)
| 801.0 | -35.6 | 1,053.4 | 69.2 | -51.6 | -54.5 | -31.1 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Aptose Biosciences (APTO)
| -70.8 | -57.0 | -69.2 | -22.8 | 196.9 | -14.7 | 61.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptose Biosciences (APTO)
|
2.0 | 4.4 | 0.0 | -25.4 | -2,650.2 | 683.2 | -- | 67.8 |
| 87.0 | 872.1 | 0.0 | -19.8 | -- | -28.1 | -- | 13.3 | |
| 5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 | |
| 9.6 | 5.8 | 14.5 | -4.4 | -28.0 | -11.8 | -- | 0.3 | |
| 15.8 | 1,460.2 | 0.0 | -168.1 | -- | -95.1 | -- | 12.9 | |
| 0.9 | 101.2 | 0.0 | -28.8 | -- | -2633.6 | -- | 1,055.0 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include... tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Read more
Chairman, President, CEO & Chief Accounting Officer
Dr. William G. Rice Ph.D.
Chairman, President, CEO & Chief Accounting Officer
Dr. William G. Rice Ph.D.
Headquarters
Toronto, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aptose Biosciences Inc (APTO) is $2.03 (NASDAQ) as of 01-May-2025 09:30 EDT. Aptose Biosciences Inc (APTO) has given a return of -51.55% in the last 3 years.
Since, TTM earnings of Aptose Biosciences Inc (APTO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Aptose Biosciences Inc (APTO) are Rs -- and Rs -- as of 02-May-2026.
Aptose Biosciences Inc (APTO) has a market capitalisation of $ 4 Mln as on 01-May-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Aptose Biosciences Inc (APTO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.